Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender

por Walmsley, Sharon, Richmond, Gary, Bredeek, Fritz, Ramgopal, Moti, Hung, Chien-Ching, Blair, Elizabeth, Kahl, Lesley, Underwood, Mark, Angelis, Kostas, Vandermeulen, Kati, Wynne, Brian, Aboud, Michael
Publicado 2017

833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results

por D’Amico, Ronald, Benn, Paul, Thiagarajah, Shanker, Ford, Susan L, Birmingham, Eileen, Upadhyay, Ojesh R, Garside, Louise, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, Spreen, William
Publicado 2021

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2

por Llibre, Josep M., López Cortés, Luis Fernando, Aylott, Alicia, Wynne, Brian, Matthews, Jessica, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, van Wyk, Jean, Kahl, Lesley P.
Publicado 2022

Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study

por Sutton, Kenneth C, De Vente, Jerome, Leblanc, Roger, Dejesus, Edwin, Smith, Graham, Mills, Anthony, Baril, Jean-Guy, St. Clair, Marty, Stancil, Britt S, Vandermeulen, Kati, Spreen, William R
Publicado 2022

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

por McComsey, Grace A., Lupo, Sergio, Parks, David, Poggio, Mónica Coronado, De Wet, Joseph, Kahl, Lesley P., Angelis, Kostas, Wynne, Brian, Vandermeulen, Kati, Gartland, Martin, Cupo, Michael, Aboud, Michael
Publicado 2018

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results...

por Mills, Anthony, Richmond, Gary J, Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Andany, Nisha, Margolis, David, Sutton, Kenneth, Wilches, Viviana, Roberts, Jeremy, McCoig, Cynthia C, Vandermeulen, Kati, Spreen, William
Publicado 2020

319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks

por Kahl, Lesley, McComsey, Grace A, Coronado Poggio, Monica, Lupo, Sergio, de Wet, Joss, Parks, David A, Wynne, Brian, Gartland, Martin, Angelis, Kostas, Aylott, Alicia, Cupo, Michael, Vandermeulen, Kati, van Wyk, Jean A, Smith, Kimberly
Publicado 2019

1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

por Teichner, Paula, Wu, Sterling, Zhang, Feifan, Dorey, David, D’Amico, Ronald, Griffith, Sandy, Sutton, Kenneth, McCoig, Cynthia C, Upadhyay, Ojesh R, Polli, Joseph, Margolis, David, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, Spreen, William, Patel, Parul
Publicado 2020

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

por Smith, Graham, Henry, Keith, Podzamczer, Daniel, Masiá, Mar, Bettacchi, Christopher, Arasteh, Keikawus, Jaeger, Hans, Khuong-Josses, Marie-Aude, Sutton, Kenneth, Zhang, Feifan, McCoig, Cynthia C, Vandermeulen, Kati, Van Solingen-Ristea, Rodica, Spreen, William, Margolis, David
Publicado 2020

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

por Mills, Anthony, Richmond, Gary J., Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Margolis, David A., Sutton, Kenneth C., Wilches, Viviana, Hatch, Sarah, Roberts, Jeremy, McCoig, Cynthia, Garris, Cindy, Vandermeulen, Kati, Spreen, William R.
Publicado 2022

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2...

por van Wyk, Jean, Orkin, Chloe, Rubio, Rafael, Bogner, Johannes, Baker, David, Khuong-Josses, Marie-Aude, Parks, David, Angelis, Konstantinos, Kahl, Lesley P., Matthews, Jessica, Wang, Ruolan, Underwood, Mark, Wynne, Brian, Nascimento, Maria-Claudia, Vandermeulen, Kati, Gartland, Martin, Smith, Kimberly Y.
Publicado 2020

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine

por Jeffrey, Jerry L., St. Clair, Marty, Wang, Ping, Wang, Chunfu, Li, Zhufang, Beloor, Jagadish, Talarico, Christine, Fridell, Robert, Krystal, Mark, White, C. Thomas, Griffith, Sandy, D’Amico, Ronald, Smith, Kimberly, Van Eygen, Veerle, Vingerhoets, Johan, Vandermeulen, Kati, Spreen, William, van Lunzen, Jan
Publicado 2022

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

por Swindells, Susan, Lutz, Thomas, Van Zyl, Lelanie, Porteiro, Norma, Stoll, Matthias, Mitha, Essack, Shon, Alyssa, Benn, Paul, Huang, Jenny O., Harrington, Conn M., Hove, Kai, Ford, Susan L., Talarico, Christine L., Chounta, Vasiliki, Crauwels, Herta, Van Solingen-Ristea, Rodica, Vanveggel, Simon, Margolis, David A., Smith, Kimberly Y., Vandermeulen, Kati, Spreen, William R.
Publicado 2022

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Lab...

por Overton, Edgar T, Richmond, Gary, Rizzardini, Giuliano, Thalme, Anders, Girard, Pierre-Marie, Wong, Alexander, Porteiro, Norma, Swindells, Susan, Reynes, Jacques, Noe, Sebastian, Harrington, Conn, Español, Carlos Martín, Acuipil, Carolina, Aksar, Asma, Wang, Yuanyuan, Ford, Susan L, Crauwels, Herta, van Eygen, Veerle, Van Solingen-Ristea, Rodica, Latham, Christine L, Thiagarajah, Shanker, D’Amico, Ronald, Smith, Kimberly Y, Vandermeulen, Kati, Spreen, William R
Publicado 2023

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, an...

por Orkin, Chloe, Schapiro, Jonathan M, Perno, Carlo F, Kuritzkes, Daniel R, Patel, Parul, DeMoor, Rebecca, Dorey, David, Wang, Yongwei, Han, Kelong, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L, Latham, Christine L, St. Clair, Marty, Polli, Joseph W, Vanveggel, Simon, Vandermeulen, Kati, D’Amico, Ronald, Garges, Harmony P, Zolopa, Andrew, Spreen, William R, van Wyk, Jean, Cutrell, Amy G
Publicado 2023

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

por Cutrell, Amy G., Schapiro, Jonathan M., Perno, Carlo F., Kuritzkes, Daniel R., Quercia, Romina, Patel, Parul, Polli, Joseph W., Dorey, David, Wang, Yongwei, Wu, Sterling, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L., Baker, Mark, Talarico, Christine L., Clair, Marty St, Jeffrey, Jerry, White, C. Thomas, Vanveggel, Simon, Vandermeulen, Kati, Margolis, David A., Aboud, Michael, Spreen, William R., van Lunzen, Jan
Publicado 2021

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

por Smith, Graham H R, Henry, W Keith, Podzamczer, Daniel, Masiá, Maria Del Mar, Bettacchi, Christopher J, Arasteh, Keikawus, Jaeger, Hans, Khuong-Josses, Marie-Aude, Montes-Ramírez, Maria Luisa, Stellbrink, Hans-Jürgen, Yazdanpanah, Yazdan, Richmond, Gary J, Sutton, Kenneth C, Zhang, Feifan, McCoig, Cynthia C, St Clair, Marty H, Vandermeulen, Kati, Van Solingen-Ristea, Rodica, Smith, Kimberly Y, Margolis, David A, Spreen, William R
Publicado 2021